Literature DB >> 21088106

Associations between genetic variation in RUNX1, RUNX2, RUNX3, MAPK1 and eIF4E and riskof colon and rectal cancer: additional support for a TGF-β-signaling pathway.

Martha L Slattery1, Abbie Lundgreen, Jennifer S Herrick, Bette J Caan, John D Potter, Roger K Wolff.   

Abstract

The Runt-related transcription factors (RUNX), mitogen-activated protein kinase (MAPK) 1 and eukaryotic translation initiation factor 4E (eIF4E) are potentially involved in tumorigenesis. We evaluated genetic variation in RUNX1 (40 tagSNPs), RUNX2 (19 tagSNPs), RUNX3 (9 tagSNPs), MAPK1 (6 tagSNPs), eIF4E (3 tagSNPs), eIF4EBP2 (2 tagSNP) and eIF4EBP3 (2 tagSNPs) to determine associations with colorectal cancer (CRC). We used data from population-based studies (colon cancer n = 1555 cases, 1956 controls; rectal cancer n = 754 cases, 959 controls with complete genotype data). Four statistically significant tagSNPs were identified with colon cancer and three tagSNPs were identified with rectal cancer. Whereas the independent risk estimates for each of the tagSNPs ranged from 1.21 to 1.52, the combined risk was greater than additive for any of the three combined high-risk genotypes {combined risk range 1.98 [95% confidence interval (CI) 1.45, 2.70] for eIF4E, RUNX1 and RUNX3 to 3.32 [95% CI 1.34, 8.23] for eIF43, RUNX2 and RUNX3}. For rectal cancer, the strongest association was detected for the combined genotype of RUNX1 and RUNX3 (odds ratio 1.87 95% CI 1.22, 2.87). Associations with specific molecular tumor phenotypes showed consistent and strong associations for CIMP+/MSI+ tumors where the risk estimates were consistently >10-fold and lower confidence bounds were over 3.00 for high-risk genotypes defined by RUNX1, RUNX2 and RUNX3. For CIMP+/KRAS2-mutated colon tumors, the combined risk for high-risk genotypes of RUNX2, eIF4E and RUNX1 was 7.47 (95% CI 1.58, 35.3). Although the associations need confirmation, the findings and their internal consistency underline the importance of genetic variation in these genes for the etiology of CRC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21088106      PMCID: PMC3047235          DOI: 10.1093/carcin/bgq245

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  36 in total

Review 1.  RUNX transcription factors as key targets of TGF-beta superfamily signaling.

Authors:  Yoshiaki Ito; Kohei Miyazono
Journal:  Curr Opin Genet Dev       Date:  2003-02       Impact factor: 5.578

2.  RUNX and cancer.

Authors:  Y Ito; M Osato; K Ito
Journal:  Ann Acad Med Singapore       Date:  2003-09       Impact factor: 2.473

3.  The RUNX3 gene--sequence, structure and regulated expression.

Authors:  C Bangsow; N Rubins; G Glusman; Y Bernstein; V Negreanu; D Goldenberg; J Lotem; E Ben-Asher; D Lancet; D Levanon; Y Groner
Journal:  Gene       Date:  2001-11-28       Impact factor: 3.688

4.  Prognostic significance of p53 mutations in colon cancer at the population level.

Authors:  Wade S Samowitz; Karen Curtin; Khe-ni Ma; Sandra Edwards; Donna Schaffer; Mark F Leppert; Martha L Slattery
Journal:  Int J Cancer       Date:  2002-06-01       Impact factor: 7.396

5.  Both the Smad and p38 MAPK pathways play a crucial role in Runx2 expression following induction by transforming growth factor-beta and bone morphogenetic protein.

Authors:  Kyeong-Sook Lee; Seung-Hyun Hong; Suk-Chul Bae
Journal:  Oncogene       Date:  2002-10-17       Impact factor: 9.867

Review 6.  The Runx genes as dominant oncogenes.

Authors:  Ewan R Cameron; Karen Blyth; Linda Hanlon; Anna Kilbey; Nancy Mackay; Monica Stewart; Anne Terry; Francois Vaillant; Sandy Wotton; James C Neil
Journal:  Blood Cells Mol Dis       Date:  2003 Mar-Apr       Impact factor: 3.039

7.  Physical activity and colorectal cancer.

Authors:  M L Slattery; S Edwards; K Curtin; K Ma; R Edwards; R Holubkov; D Schaffer
Journal:  Am J Epidemiol       Date:  2003-08-01       Impact factor: 4.897

Review 8.  Runx transcription factors and the developmental balance between cell proliferation and differentiation.

Authors:  James A Coffman
Journal:  Cell Biol Int       Date:  2003       Impact factor: 3.612

9.  Energy balance and rectal cancer: an evaluation of energy intake, energy expenditure, and body mass index.

Authors:  Martha L Slattery; Bette J Caan; Joan Benson; Maureen Murtaugh
Journal:  Nutr Cancer       Date:  2003       Impact factor: 2.900

10.  Elevated ERK-MAP kinase activity protects the FOS family member FRA-1 against proteasomal degradation in colon carcinoma cells.

Authors:  Emmanuel Vial; Christopher J Marshall
Journal:  J Cell Sci       Date:  2003-12-15       Impact factor: 5.285

View more
  40 in total

1.  Investigation of methylation and protein expression of the Runx3 gene in colon carcinogenesis.

Authors:  Shao-Ya He; Ren-Fa Jiang; Jie Jiang; Yang-Sheng Xiang; Ling Wang
Journal:  Biomed Rep       Date:  2015-06-17

Review 2.  Posttranslational modifications of RUNX1 as potential anticancer targets.

Authors:  S Goyama; G Huang; M Kurokawa; J C Mulloy
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

3.  Genetic variation in the transforming growth factor-β signaling pathway and survival after diagnosis with colon and rectal cancer.

Authors:  Martha L Slattery; Abbie Lundgreen; Jennifer S Herrick; Roger K Wolff; Bette J Caan
Journal:  Cancer       Date:  2011-03-01       Impact factor: 6.860

4.  A pathway approach to evaluating the association between the CHIEF pathway and risk of colorectal cancer.

Authors:  Martha L Slattery; Roger K Wolff; Abbie Lundgreen
Journal:  Carcinogenesis       Date:  2014-10-20       Impact factor: 4.944

5.  Defining a tissue stem cell-driven Runx1/Stat3 signalling axis in epithelial cancer.

Authors:  Cornelia Johanna Franziska Scheitz; Tae Seung Lee; David James McDermitt; Tudorita Tumbar
Journal:  EMBO J       Date:  2012-10-02       Impact factor: 11.598

6.  Genomic aberrations occurring in subsets of serrated colorectal lesions but not conventional adenomas.

Authors:  Andrea N Burnett-Hartman; Polly A Newcomb; John D Potter; Michael N Passarelli; Amanda I Phipps; Michelle A Wurscher; William M Grady; Lee-Ching Zhu; Melissa P Upton; Karen W Makar
Journal:  Cancer Res       Date:  2013-03-28       Impact factor: 12.701

Review 7.  New insights into the role of Runx1 in epithelial stem cell biology and pathology.

Authors:  Cornelia Johanna Franziska Scheitz; Tudorita Tumbar
Journal:  J Cell Biochem       Date:  2013-05       Impact factor: 4.429

8.  The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion.

Authors:  Mamadou Keita; Magdalena Bachvarova; Chantale Morin; Marie Plante; Jean Gregoire; Marie-Claude Renaud; Alexandra Sebastianelli; Xuan Bich Trinh; Dimcho Bachvarov
Journal:  Cell Cycle       Date:  2013-02-26       Impact factor: 4.534

9.  Clinical significance of RUNX2 expression in patients with nonsmall cell lung cancer: a 5-year follow-up study.

Authors:  Hong Li; Ren-Jie Zhou; Guo-Qiang Zhang; Jian-Ping Xu
Journal:  Tumour Biol       Date:  2013-03-08

Review 10.  The RUNX family in breast cancer: relationships with estrogen signaling.

Authors:  N-O Chimge; B Frenkel
Journal:  Oncogene       Date:  2012-10-08       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.